Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | TGM2 | P21980 | 12/20 | 0.53 |
| ▸ | F13A1 | P00488 | 9/20 | 0.53 |
| ▸ | TGM1 | P22735 | 6/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.50 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10042200 | 0.88 | TDP1 (0.65) | EPHX2TGM2F13A1TGM1TGM3 | |
| SCHEMBL309691 | 0.85 | EPHX2 (0.55) | EPHX2TGM2F13A1TGM1GPR119 | |
| SCHEMBL10042196 | 0.82 | USP2 (0.50) | EPHX2GPR119TDP1GAAKMT2A | |
| SCHEMBL2376710 | 0.82 | ABL1 (0.59) | TGM2F13A1TGM1KMT2AMEN1 | |
| SCHEMBL2512179 | 0.81 | TGM2 (0.55) | EPHX2TGM2F13A1TGM1GPR119 | |
| SCHEMBL18410584 | 0.81 | TGM2 (0.65) | TGM2F13A1TGM1GAAKMT2A | |
| SCHEMBL2226727 | 0.81 | TGM2 (0.64) | EPHX2TGM2F13A1TGM1TGM3 | |
| SCHEMBL31165481 | 0.79 | TGM2 (0.56) | TGM2F13A1TGM1GPR119KMT2A | |
| SCHEMBL2378926 | 0.79 | TGM2 (0.56) | TGM2F13A1TGM1GPR119KMT2A | |
| SCHEMBL14490221 | 0.78 | ABL1 (0.55) | TGM2F13A1TGM1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536183-B2 | 3-pyridylcarbonyl-piperazinylsulfonyl derivatives | Convergence Pharmaceuticals Limited (GB) | 2013-09-17 | — | — | US | disclosed |
| US-20120302746-A1 | 3-PYRIDYLCARBONYL-PIPERAZINYLSULFONYL DERIVATIVES | BESWICK PAUL JOHN (GB) | 2012-11-29 | — | — | US | disclosed |
| US-8288388-B2 | 3-pyridylcarbonyl-piperazinylsulfonyl derivatives | Convergence Pharmaceuticals Limited (GB) | 2012-10-16 | — | — | US | disclosed |
| US-8093249-B2 | Pyrazolo[1,5-A]pyrimidine-carbonyl-piperazine derivatives | Convergence Pharmaceuticals Limited (GB) | 2012-01-10 | — | — | US | disclosed |
| US-20100022555-A1 | Novel Derivatives | Convergence Pharmaceuticals Limited (GB) | 2010-01-28 | — | — | US | disclosed |
| US-20100016330-A1 | Novel Derivatives | Convergence Pharmaceuticals Limited (GB) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016330-A1 | Novel Derivatives | CACNB2, CACNA1B, CACNA1D | EPHX2 3915/4885TGM2 2597/4885F13A1 4570/4885 |
| US-20100022555-A1 | Novel Derivatives | CACNB2, CACNA1B, CACNA1D | EPHX2 3915/4885TGM2 2597/4885F13A1 4570/4885 |
| US-20120302746-A1 | 3-PYRIDYLCARBONYL-PIPERAZINYLSULFONYL DERIVATIVES | CACNB2, CACNA1C, KCNJ2 | EPHX2 4441/4885TGM2 2441/4885F13A1 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.